CORZ / Core Scientific, Inc. - SEC-Einreichungen, Jahresbericht, Proxy Statement

Core Scientific Appoints Steve Smith to Board of Directors Industry Veteran with 35+ Years of Leadership Experience in Data Center, Digital Infrastructure and Technology Industries AUSTIN, Texas, May 26, 2026 – Core Scientific, Inc. (Nasdaq: CORZ) (“

ex991-ssboardappointment Core Scientific Appoints Steve Smith to Board of Directors Industry Veteran with 35+ Years of Leadership Experience in Data Center, Digital Infrastructure and Technology Industries AUSTIN, Texas, May 26, 2026 – Core Scientific, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2026 Core Scientific, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2026 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2026 Core Scientific, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2026 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission File

Core Scientific Plans Expansion to 1.5 Gigawatts of Gross Power at Muskogee, Oklahoma Campus AUSTIN, Texas, May 6, 2026 – Core Scientific, Inc. (Nasdaq: CORZ) (“Core Scientific” or the “Company”), a leader in digital infrastructure for high-density c

exhibit991polarispressre Core Scientific Plans Expansion to 1.5 Gigawatts of Gross Power at Muskogee, Oklahoma Campus AUSTIN, Texas, May 6, 2026 – Core Scientific, Inc. (Nasdaq: CORZ) (“Core Scientific” or the “Company”), a leader in digital infrastructure for high-density colocation (“HDC”), today announced a multi-tiered strategy to scale its Muskogee, Oklahoma campus to approximately 1.5 gigawa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2026 Core Scientific, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2026 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2026 Core Scientific, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2026 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission File

CORE SCIENTIFIC FINANCE I LLC CORE SCIENTIFIC FINANCE HOLDING LLC AND THE SUBSIDIARY GUARANTORS PARTY HERETO 7.750% SENIOR SECURED NOTES DUE 2031 Dated as of May 6, 2026 WILMINGTON SAVINGS FUND SOCIETY, FSB, as Trustee, WILMINGTON SAVINGS FUND SOCIET

EX-4.1 Exhibit 4.1 Execution Version CORE SCIENTIFIC FINANCE I LLC CORE SCIENTIFIC FINANCE HOLDING LLC AND THE SUBSIDIARY GUARANTORS PARTY HERETO 7.750% SENIOR SECURED NOTES DUE 2031 INDENTURE Dated as of May 6, 2026 WILMINGTON SAVINGS FUND SOCIETY, FSB, as Trustee, and WILMINGTON SAVINGS FUND SOCIETY, FSB, as Collateral Agent TABLE OF CONTENTS Page Article 1 DEFINITIONS 1 Section 1.01 Definitions

First Quarter Fiscal 2026 Earnings Call May 6, 2026 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, (the “Securities Act”) and Section 21E

q1fy26earningsdeck First Quarter Fiscal 2026 Earnings Call May 6, 2026 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”).

Core Scientific Announces Pricing of $3.3 Billion of Senior Secured Notes

EX-99.1 Exhibit 99.1 Core Scientific Announces Pricing of $3.3 Billion of Senior Secured Notes AUSTIN, Texas, April 22, 2026— Core Scientific, Inc. (Nasdaq: CORZ) (“Core Scientific” or the “Company”), a leader in digital infrastructure for high-density colocation (“HDC”), today announced that its wholly-owned subsidiary, Core Scientific Finance I LLC (the “Issuer”), has priced an offering of $3.3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2026 Core Scientific, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2026 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission File

Core Scientific Announces First Quarter Fiscal Year 2026 Results

Core Scientific Announces First Quarter Fiscal Year 2026 Results Recent Developments •Strengthened the capital structure through today’s closing of a $3.

Core Scientific, Inc./tx

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00

Execution Version MEMBERSHIP INTEREST PURCHASE AGREEMENT This MEMBERSHIP INTEREST PURCHASE AGREEMENT (this “Agreement”), dated as of the 26th day of December, 2025 (the “Effective Date”), is entered into by and among MCCALL FAMILY LIMITED PARTNERSHIP

exhibit102membershipinte Execution Version MEMBERSHIP INTEREST PURCHASE AGREEMENT This MEMBERSHIP INTEREST PURCHASE AGREEMENT (this “Agreement”), dated as of the 26th day of December, 2025 (the “Effective Date”), is entered into by and among MCCALL FAMILY LIMITED PARTNERSHIP, a Texas limited partnership (“Seller Group”), TELIOS QUINLAN ONE, LLC, a Delaware limited liability company (the “Company”), and CORE SCIENTIFIC, INC.

Execution Version AGREEMENT AND PLAN OF MERGER BY AND AMONG TOP ACCESS ENTERPRISES LIMITED, POLARIS DS LLC, CORE SCIENTIFIC INC., POLAR MERGER SUB, LLC, AND Solely for purposes of Article XI (and Article I and Article XII to the extent relating there

exhibit21polaris-mergera Execution Version AGREEMENT AND PLAN OF MERGER BY AND AMONG TOP ACCESS ENTERPRISES LIMITED, POLARIS DS LLC, CORE SCIENTIFIC INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2026 Core Scientific, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2026 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission Fi

Core Scientific Plans Expansion to 1.5 Gigawatts of Gross Power at Pecos, Texas Campus AUSTIN, Texas, April 27, 2026 – Core Scientific, Inc. (Nasdaq: CORZ) (“Core Scientific” or the “Company”), a leader in digital infrastructure for high-density colo

exhibit991-pecosexpansio Core Scientific Plans Expansion to 1.5 Gigawatts of Gross Power at Pecos, Texas Campus AUSTIN, Texas, April 27, 2026 – Core Scientific, Inc. (Nasdaq: CORZ) (“Core Scientific” or the “Company”), a leader in digital infrastructure for high-density colocation (“HDC”), today announced a multi-tiered strategy to scale its Pecos, Texas campus to approximately 1.5 gigawatts (“GW”

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2026 Core Scientific, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2026 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2026 Core Scientific, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2026 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission Fi

Supplemental Information regarding Core Scientific, Inc., dated April 21, 2026

EX-99.2 Exhibit 99.2 Supplemental Information regarding Core Scientific, Inc., dated April 21, 2026 The supplemental information regarding Core Scientific, Inc. (“Core Scientific”) set forth below shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of any securities in any state or jurisdiction in which such an offer, solicitation

Core Scientific Announces Proposed Offering of $3.3 Billion of Senior Secured Notes

EX-99.1 Exhibit 99.1 Core Scientific Announces Proposed Offering of $3.3 Billion of Senior Secured Notes AUSTIN, Texas, April 21, 2026 — Core Scientific, Inc. (Nasdaq: CORZ) (“Core Scientific” or the “Company”), a leader in digital infrastructure for high-density colocation (“HDC”), today announced that its wholly-owned subsidiary, Core Scientific Finance I LLC (the “Issuer”), intends to offer, su

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEFA14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

ARS

UNITEDSTAT T T ES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM10-K (MarkOne) ☒ ANNUALREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF 1934 ForthefiscalyearendedDecember31,2025 OR TRANS R R ITIONREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACT OF1934 Forthetransitionperiodfrom to Commissionfilenumber001-40046 CoreScientific,Inc. (Exactnameofregistrantasspecifiedin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2026 Core Scientific, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2026 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission Fi

Core Scientific Expands Strategic Financing Facility to $1 Billion with Additional $500 Million Commitment from J.P. Morgan AUSTIN, Texas, March 23, 2026 – Core Scientific, Inc. (Nasdaq: CORZ) (“Core Scientific” or the “Company”), a leader in digital

exhibit991-amendno1credi Core Scientific Expands Strategic Financing Facility to $1 Billion with Additional $500 Million Commitment from J.

333370682 v3 Execution Version AMENDMENT NO. 1 TO DELAYED-DRAW BRIDGE CREDIT AGREEMENT AMENDMENT NO. 1, dated as of March 18, 2026 (this “Amendment”) to the Delayed- Draw Bridge Credit Agreement, dated as of March 4, 2026, among Core Scientific, Inc.

exhibit101-amendmentno1e 333370682 v3 Execution Version AMENDMENT NO. 1 TO DELAYED-DRAW BRIDGE CREDIT AGREEMENT AMENDMENT NO. 1, dated as of March 18, 2026 (this “Amendment”) to the Delayed- Draw Bridge Credit Agreement, dated as of March 4, 2026, among Core Scientific, Inc., a Delaware cor- poration (the “Borrower”), Morgan Stanley Senior Funding, Inc., as Administrative Agent (in such capac- ity

Core Scientific, Inc./tx

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission

Execution Version DELAYED-DRAW BRIDGE CREDIT AGREEMENT dated as of March 4, 2026 among CORE SCIENTIFIC, INC., as Borrower, THE LENDERS PARTY HERETO FROM TIME TO TIME, and MORGAN STANLEY SENIOR FUNDING, INC., as Administrative Agent and as Collateral

exhibit101bridgecreditag Execution Version DELAYED-DRAW BRIDGE CREDIT AGREEMENT dated as of March 4, 2026 among CORE SCIENTIFIC, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2026 Core Scientific, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2026 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission Fil

Core Scientific Secures Strategic Financing with Morgan Stanley for Up To $1 Billion AUSTIN, Texas, March 5, 2026 – Core Scientific, Inc. (Nasdaq: CORZ) (“Core Scientific” or the “Company”), a leader in digital infrastructure for high-density colocat

exhibit991pressreleasebr Core Scientific Secures Strategic Financing with Morgan Stanley for Up To $1 Billion AUSTIN, Texas, March 5, 2026 – Core Scientific, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commi

Core Scientific, Inc./tx

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-400

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2026 Core Scientific, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2026 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission

Core Scientific Announces Fourth Quarter Fiscal Year 2025 Results

Core Scientific Announces Fourth Quarter Fiscal Year 2025 Results Key Highlights •New Top-market Site: Announced an agreement to expand into Hunt County, Texas, which is expected to support ~430 MW of gross power capacity, with an approved ERCOT interconnection ramp schedule.

Subsidiaries of Core Scientific, Inc.

Exhibit 21.1 Subsidiaries of Core Scientific, Inc. Name of Subsidiary Jurisdiction of Incorporation American Property Acquisition, LLC Delaware American Property Acquisition I, LLC North Carolina American Property Acquisitions VII, LLC Georgia Core Scientific Mining (Oklahoma) LLC Delaware

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to C

Fourth Quarter Fiscal 2025 Earnings Call March 2, 2026 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, (the “Securities Act”) and Section

q4fy25earningsdeckvfinal Fourth Quarter Fiscal 2025 Earnings Call March 2, 2026 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”).

COOPERATION AGREEMENT

Exhibit 10.1 COOPERATION AGREEMENT This Cooperation Agreement (this “Agreement”) is made and entered into as of February 18, 2026 by and between Core Scientific, Inc., a Delaware corporation (the “Company”), and Two Seas Capital LP, a Delaware limited partnership (“Two Seas”), with respect to the matters set forth below. The Company and Two Seas are each herein referred to as a “party” and, collec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2026 Core Scientif

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2026 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2026 Core Scientific

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2026 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission

COOPERATION AGREEMENT

Exhibit 10.1 COOPERATION AGREEMENT This Cooperation Agreement (this “Agreement”) is made and entered into as of February 18, 2026 by and between Core Scientific, Inc., a Delaware corporation (the “Company”), and Two Seas Capital LP, a Delaware limited partnership (“Two Seas”), with respect to the matters set forth below. The Company and Two Seas are each herein referred to as a “party” and, collec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2025 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2025 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission

Core Scientific Announces Termination of Merger Agreement with CoreWeave

Exhibit 99.1 Core Scientific Announces Termination of Merger Agreement with CoreWeave AUSTIN, Texas, October 30, 2025 - Core Scientific, Inc. (NASDAQ: CORZ) (“Core Scientific” or the “Company”), a leader in digital infrastructure for high-density colocation services and digital asset mining, previously announced that at a special meeting of Core Scientific stockholders, the Company did not receive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2025 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission

Adam Sullivan, CEO Jim Nygaard, CFO Matt Brown, COO October 30, 2025 Investor Presentation 2 FORWARD-LOOKING STATEMENTS This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securiti

Exhibit 99.1 Adam Sullivan, CEO Jim Nygaard, CFO Matt Brown, COO October 30, 2025 Investor Presentation 2 FORWARD-LOOKING STATEMENTS This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding projections, estimates and forecasts of revenue and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2025 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission

Core Scientific Announces Preliminary Results of Special Meeting of Stockholders

Exhibit 99.1 Core Scientific Announces Preliminary Results of Special Meeting of Stockholders AUSTIN, Texas, October 30, 2025 – Core Scientific, Inc. (Nasdaq: CORZ) (“Core Scientific” or the “Company”), a leader in digital infrastructure for high-density colocation services and digital asset mining, today announced that at a special meeting of Core Scientific stockholders (the “Special Meeting”) h

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant þ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement þ Definitive Additional Materials o Soliciting Material Under Rule 14a-12 Core Scientific, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2025 Core Scientific,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2025 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe

Core Scientific Announces Fiscal Third Quarter 2025 Results

Core Scientific Announces Fiscal Third Quarter 2025 Results AUSTIN, Texas, October 24, 2025 - Core Scientific, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2025 Core Scientific,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2025 Core Scientific, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40046 86-1243837 (State or Other Jurisdiction of Incorporation) (Commission

CoreWeave Comments on Proxy Advisor Recommendations Regarding Proposed Acquisition of Core Scientific CoreWeave Disagrees with the Recommendations Against the Transaction Believes the Agreed Upon Transaction Represents Fair Value of the Two Companies

Filed by CoreWeave, Inc. pursuant to Rule 425 of the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Core Scientific, Inc./tx (Commission File No.: 001-40046) Date: October 22, 2025 The following press release was issued by CoreWeave, Inc. on October 22, 2025 in connection with CoreWeave’s proposed acqu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2025 Core Scientific,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2025 Core Scientific, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40046 86-1243837 (State or Other Jurisdiction of Incorporation) (Commission

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant þ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement þ Definitive Additional Materials o Soliciting Material Under Rule 14a-12 Core Scientific, Inc.

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ¨ Filed by a Party other than the Registrant þ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement þ Definitive Additional Materials ¨ Soliciting Material Under Rule 14a-12 Core Scientific, Inc.

Filed by CoreWeave, Inc.

Filed by CoreWeave, Inc. pursuant to Rule 425 of the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Core Scientific, Inc./tx (Commission File No.: 001-40046) Date: October 17, 2025 The following communication was posted by CoreWeave, Inc. on its LinkedIn account on October 16, 2025 in relation to CoreW

CoreWeave Reaffirms Strategic Rationale of its Proposed Acquisition and Financial Benefits to Core Scientific Stockholders Urges Core Scientific Stockholders to Vote FOR the Proposed Transaction

Filed by CoreWeave, Inc. pursuant to Rule 425 of the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Core Scientific, Inc./tx (Commission File No.: 001-40046) Date: October 16, 2025 The following press release was issued by CoreWeave, Inc. on October 16, 2025 in connection with CoreWeave’s proposed acqu

Proposed Merger between Core Scientific and CoreWeave October 2025 Executive Summary 2 The Core Scientific Board of Directors (the “Board”) unanimously determined that the proposed transaction with CoreWeave represents the best available alternative

Exhibit 99.1 Proposed Merger between Core Scientific and CoreWeave October 2025 Executive Summary 2 The Core Scientific Board of Directors (the “Board”) unanimously determined that the proposed transaction with CoreWeave represents the best available alternative for all Core Scientific stockholders and recommends all stockholders vote FOR the transaction 1 The proposed transaction provides signif

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2025 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2025 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission

Proposed Merger between Core Scientific and CoreWeave October 2025 Executive Summary 2 The Core Scientific Board of Directors (the “Board”) unanimously determined that the proposed transaction with CoreWeave represents the best available alternative

Exhibit 99.1 Proposed Merger between Core Scientific and CoreWeave October 2025 Executive Summary 2 The Core Scientific Board of Directors (the “Board”) unanimously determined that the proposed transaction with CoreWeave represents the best available alternative for all Core Scientific stockholders and recommends all stockholders vote FOR the transaction 1 The proposed transaction provides signif

Proposed Merger between Core Scientific and CoreWeave October 2025 Executive Summary 2 The Core Scientific Board of Directors (the “Board”) unanimously determined that the proposed transaction with CoreWeave represents the best available alternative

Exhibit 99.1 Proposed Merger between Core Scientific and CoreWeave October 2025 Executive Summary 2 The Core Scientific Board of Directors (the “Board”) unanimously determined that the proposed transaction with CoreWeave represents the best available alternative for all Core Scientific stockholders and recommends all stockholders vote FOR the transaction 1 The proposed transaction provides signif

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2025 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission

Proposed Merger between Core Scientific and CoreWeave October 2025 Executive Summary 2 The Core Scientific Board of Directors (the “Board”) unanimously determined that the proposed transaction with CoreWeave represents the best available alternative

Exhibit 99.1 Proposed Merger between Core Scientific and CoreWeave October 2025 Executive Summary 2 The Core Scientific Board of Directors (the “Board”) unanimously determined that the proposed transaction with CoreWeave represents the best available alternative for all Core Scientific stockholders and recommends all stockholders vote FOR the transaction 1 The proposed transaction provides signif

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2025 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission

© All rights reserved. Two Seas Capital LP A FLAWED PROCESS, A DEFICIENT STRUCTURE AND AN INADEQUATE PRICE INVESTOR PRESENTATION TWO SEAS CAPITAL LP OCTOBER 2025 STOCKHOLDERS SHOULD VOTE AGAINST THE PROPOSED ACQUISITION OF CORE SCIENTIFIC

Exhibit 1 © All rights reserved. Two Seas Capital LP A FLAWED PROCESS, A DEFICIENT STRUCTURE AND AN INADEQUATE PRICE INVESTOR PRESENTATION TWO SEAS CAPITAL LP OCTOBER 2025 STOCKHOLDERS SHOULD VOTE AGAINST THE PROPOSED ACQUISITION OF CORE SCIENTIFIC © All rights reserved. Two Seas Capital LP TABLE OF CONTENTS INVESTOR PRESENTATION PAGE 3 Executive Summary 01 PAGE 14 The Board’s Deal Process and Neg

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ¨ Filed by a Party other than the Registrant þ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement þ Definitive Additional Materials ¨ Soliciting Material Under Rule 14a-12 Core Scientific, Inc.

INVESTOR PRESENTATION PDF

© All rights reserved. Two Seas Capital LP A FLAWED PROCESS, A DEFICIENT STRUCTURE AND AN INADEQUATE PRICE I N V E S TO R P R E S E N TA TI O N TWO SEAS CAPITAL LP O C T O B E R 2 0 2 5 STOCKHOLDERS SHOULD VOTE AGAINST THE PROPOSED ACQUISITION OF CORE SCIENTIFIC© All rights reserved. Two Seas Capital LP TABLE OF CONTENTS I N V E S TO R P R E S E N TA TI O N 01 Executive Summary PAGE 3 02 The Board

© All rights reserved. Two Seas Capital LP A FLAWED PROCESS, A DEFICIENT STRUCTURE AND AN INADEQUATE PRICE INVESTOR PRESENTATION TWO SEAS CAPITAL LP OCTOBER 2025 STOCKHOLDERS SHOULD VOTE AGAINST THE PROPOSED ACQUISITION OF CORE SCIENTIFIC

Exhibit 1 © All rights reserved. Two Seas Capital LP A FLAWED PROCESS, A DEFICIENT STRUCTURE AND AN INADEQUATE PRICE INVESTOR PRESENTATION TWO SEAS CAPITAL LP OCTOBER 2025 STOCKHOLDERS SHOULD VOTE AGAINST THE PROPOSED ACQUISITION OF CORE SCIENTIFIC © All rights reserved. Two Seas Capital LP TABLE OF CONTENTS INVESTOR PRESENTATION PAGE 3 Executive Summary 01 PAGE 14 The Board’s Deal Process and Neg

Filed by CoreWeave, Inc.

Filed by CoreWeave, Inc. pursuant to Rule 425 of the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Core Scientific, Inc./tx (Commission File No.: 001-40046) Date: October 10, 2025 The following communication was posted by CoreWeave, Inc. on its LinkedIn account on October 10, 2025 in relation to an in

INFORMATION ABOUT THE PARTICIPANTS

Exhibit 2 INFORMATION ABOUT THE PARTICIPANTS This proxy solicitation is being made by Two Seas Capital LP (“Two Seas Capital”), Two Seas Capital GP LLC, a Delaware limited liability company (“Two Seas GP”), and Sina Toussi (“Mr.

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ¨ Filed by a Party other than the Registrant þ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement þ Definitive Additional Materials ¨ Soliciting Material Under Rule 14a-12 Core Scientific, Inc.

Filed by CoreWeave, Inc.

Filed by CoreWeave, Inc. pursuant to Rule 425 of the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Core Scientific, Inc./tx (Commission File No.: 001-40046) Date: October 7, 2025 The following is a transcript of an interview with Michael Intrator, Chief Executive Officer of CoreWeave, Inc. on October

Filed by CoreWeave, Inc.

Filed by CoreWeave, Inc. pursuant to Rule 425 of the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Core Scientific, Inc./tx (Commission File No.: 001-40046) Date: October 7, 2025 The following is an article posted on Bloomberg in relation to an interview with Michael Intrator, Chief Executive Officer

Filed by CoreWeave, Inc.

Filed by CoreWeave, Inc. pursuant to Rule 425 of the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Core Scientific, Inc./tx (Commission File No.: 001-40046) Date: October 7, 2025 The following communication was posted by CoreWeave, Inc. on its LinkedIn account on October 7, 2025 in connection with Cor

Filed by CoreWeave, Inc.

Filed by CoreWeave, Inc. pursuant to Rule 425 of the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Core Scientific, Inc./tx (Commission File No.: 001-40046) Date: October 7, 2025 The following communication was posted by Michael Intrator, Chief Executive Officer of CoreWeave, Inc., on his LinkedIn acc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☑ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defin

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☑ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☑ Definitive Additional Materials ☐ Soliciting Material Under Rule 14a-12 Core Scientific, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Ru

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☑ Check the appropriate box: ☑ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2025 Core Scientific, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2025 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001

Core Scientific Announces Fiscal Second Quarter 2025 Results

Core Scientific Announces Fiscal Second Quarter 2025 Results AUSTIN, Texas, August 8, 2025 - Core Scientific, Inc.

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ¨ Filed by a Party other than the Registrant þ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement ¨ Definitive Additional Materials þ Soliciting Material Under Rule 14a-12 Core Scientific, Inc.

Filed by CoreWeave, Inc.

Filed by CoreWeave, Inc. pursuant to Rule 425 of the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Core Scientific, Inc./tx (Commission File No.: 001-40046) Date: July 14, 2025 The following communication was posted by CoreWeave, Inc. on its X account on July 11, 2025 in connection with CoreWeave’s pr

Filed by CoreWeave, Inc.

Filed by CoreWeave, Inc. pursuant to Rule 425 of the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Core Scientific, Inc./tx (Commission File No.: 001-40046) Date: July 14, 2025 The following communication was posted by CoreWeave, Inc. on its LinkedIn account on July 11, 2025 in connection with CoreWea

###

Filed by CoreWeave, Inc. pursuant to Rule 425 of the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Core Scientific, Inc./tx (Commission File No.: 001-40046) Date: July 14, 2025 The following is a transcript of an interview with Michael Intrator, Chief Executive Officer of CoreWeave, Inc. on July 8, 20

Filed by CoreWeave, Inc.

Filed by CoreWeave, Inc. pursuant to Rule 425 of the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Core Scientific, Inc./tx (Commission File No.: 001-40046) Date: July 9, 2025 The following message was distributed by executive officers and founders of CoreWeave, Inc. to employees of Core Scientific, I

Filed by CoreWeave, Inc.

Filed by CoreWeave, Inc. pursuant to Rule 425 of the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Core Scientific, Inc./tx (Commission File No.: 001-40046) Date: July 9, 2025 The following communication was posted on CoreWeave, Inc.’s LinkedIn account on July 8, 2025 in connection with CoreWeave’s pr

Filed by CoreWeave, Inc.

Filed by CoreWeave, Inc. pursuant to Rule 425 of the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Core Scientific, Inc./tx (Commission File No.: 001-40046) Date: July 7, 2025 The following communication was posted on LinkedIn by Michael Intrator, Chief Executive Officer of CoreWeave, Inc., on July7,

Filed by CoreWeave, Inc.

Filed by CoreWeave, Inc. pursuant to Rule 425 of the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Core Scientific, Inc./tx (Commission File No.: 001-40046) Date: July 7, 2025 The following communication was distributed by CoreWeave, Inc. to its employees on July 7, 2025 in connection with CoreWeave's

###

Filed by CoreWeave, Inc. pursuant to Rule 425 of the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Core Scientific, Inc./tx (Commission File No.: 001-40046) Date: July 8, 2025 The following is a transcript of an interview with Michael Intrator, Chief Executive Officer of CoreWeave, Inc. on July 7, 202

Filed by CoreWeave, Inc.

Filed by CoreWeave, Inc. pursuant to Rule 425 of the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Core Scientific, Inc./tx (Commission File No.: 001-40046) Date: July 8, 2025 The following communication was posted on CoreWeave, Inc.’s X account on July 8, 2025 in connection with CoreWeave’s proposed

Filed by CoreWeave, Inc.

Filed by CoreWeave, Inc. pursuant to Rule 425 of the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Core Scientific, Inc./tx (Commission File No.: 001-40046) Date: July 7, 2025 The following communication was posted on LinkedIn by Michael Intrator, Chief Executive Officer of CoreWeave, Inc., on July7,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2025 Core Scientific, Inc

425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2025 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission

CoreWeave to Acquire Core Scientific Verticalizes Data Center Ownership to Help Future-Proof Revenue Growth and Enhance Core Profitability

EX-99.1 Exhibit 99.1 CoreWeave to Acquire Core Scientific Verticalizes Data Center Ownership to Help Future-Proof Revenue Growth and Enhance Core Profitability Livingston, NJ and Austin, TX – July 7, 2025 – CoreWeave (NASDAQ: CRWV), the AI Hyperscaler™, and Core Scientific (NASDAQ: CORZ), a leading data center infrastructure provider, today announced that they have signed a definitive agreement un

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2025 Core Scientific, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2025 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission File

Filed by CoreWeave, Inc.

Filed by CoreWeave, Inc. pursuant to Rule 425 of the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Core Scientific, Inc./tx (Commission File No.: 001-40046) Date: July 7, 2025 The following communication was posted on X by CoreWeave, Inc. on July 7, 2025 in connection with CoreWeave's proposed acquisi

Filed by CoreWeave, Inc.

Filed by CoreWeave, Inc. pursuant to Rule 425 of the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Core Scientific, Inc. (Commission File No.: 001-40046) Date: July 7, 2025 The following presentation was posted on CoreWeave, Inc.'s website on July 7, 2025 in connection with CoreWeave's proposed acquis

Filed by Core Scientific, Inc.

Filed by Core Scientific, Inc. (Commission File No.: 001-40046) Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Core Scientific, Inc. (Commission File No.: 001-40046) The following communication was made available by Core Scientific, Inc. to its employees on July 7, 2025. To: All Core Scientif

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2025 Core Scientific, Inc

425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2025 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission

Filed by Core Scientific, Inc.

425 Filed by Core Scientific, Inc. (Commission File No.: 001-40046) Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Core Scientific, Inc. (Commission File No.: 001-40046) The following set of Frequently Asked Questions (“FAQs”) were distributed by Core Scientific, Inc. to its employees on July

Agreement and Plan of Merger, dated as of July 7, 2025, by and among CoreWeave, Inc., Miami Merger Sub I, Inc. and Core Scientific, Inc.*

Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among COREWEAVE, INC, MIAMI MERGER SUB I, INC., and CORE SCIENTIFIC, INC. dated as of July 7, 2025 TABLE OF CONTENTS Page No. ARTICLE I DEFINITIONS 2 Section 1.01. Certain Definitions 2 Section 1.02. Other Defined Terms 18 Section 1.03. Other Definitional Provisions 20 ARTICLE II THE MERGER 21 Section 2.01. The Merger 21 Section 2.0

Filed by CoreWeave, Inc.

Filed by CoreWeave, Inc. pursuant to Rule 425 of the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Core Scientific, Inc./tx (Commission File No.: 001-40046) Date: July 7, 2025 The following blog was posted by Michael Intrator, Chief Executive Officer of CoreWeave, Inc., on CoreWeave’s website on July

Filed by CoreWeave, Inc.

Filed by CoreWeave, Inc. pursuant to Rule 425 of the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Core Scientific, Inc./tx (Commission File No.: 001-40046) Date: July 7, 2025 The following is a transcript of an investor call held by CoreWeave, Inc. on July 7, 2025. The speakers are identified therein

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2025 Core Scientific, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2025 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission File

-2-

Filed by Core Scientific, Inc. (Commission File No.: 001-40046) Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Core Scientific, Inc. (Commission File No.: 001-40046) The following communications were made by Core Scientific, Inc. in connection with the proposed acquisition of Core Scientific,

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2025 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission File

Third Amended and Restated Bylaws of Core Scientific, Inc.

Exhibit 3.2 THIRD AMENDED AND RESTATED BYLAWS OF CORE SCIENTIFIC, INC. (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be as set forth in the Fourth Amended and Restated Certificate of Incorporation of the corporation, as the same may be amended or restated from time to time (the “Certificate of Incorp

Fourth Amended and Restated Certificate of Incorporation of Core Scientific, Inc.

Exhibit 3.1 FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CORE SCIENTIFIC, INC. The undersigned, being the Secretary of Core Scientific, Inc. (originally incorporated under the name Power & Digital Infrastructure Acquisition Corp.) (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of the Delaware (as it now exist

Filing Fee Table.

Calculation of Filing Fee Tables S-8 Core Scientific, Inc./tx Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.00001 par value per share Other 48,000,000 $ 10.61 $ 509,280,000.00 0.0001531 $ 77,970.77 T

As filed with the Securities and Exchange Commission on May 23, 2025

As filed with the Securities and Exchange Commission on May 23, 2025 No. 333-      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CORE SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 86-1243837 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Ide

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission File

Core Scientific Appoints Elizabeth Crain to Board of Directors Jordan Levy Elected Chairman of the Board

Exhibit 99.2 May 16, 2025 Core Scientific Appoints Elizabeth Crain to Board of Directors Jordan Levy Elected Chairman of the Board AUSTIN, Texas, May 16, 2025 - Core Scientific, Inc. (NASDAQ: CORZ), a leader in digital infrastructure for high-density colocation services and digital asset mining, today announced the appointment of Elizabeth Crain to its Board of Directors, effective immediately. Ms

Core Scientific Announces Departure of Board Member Todd Becker

Exhibit 99.1 Core Scientific Announces Departure of Board Member Todd Becker AUSTIN, Texas, May 13, 2025 - Core Scientific, Inc. (NASDAQ: CORZ), a leader in digital infrastructure for high-density colocation services and digital asset mining, today announced that Todd Becker will be stepping down from its Board of Directors, effective immediately. Mr. Becker joined the Board in January 2024 and ha

Core Scientific, Inc. Amended and Restated 2024 Stock Incentive Plan, dated May 12, 2025.

CORE SCIENTIFIC, INC. AMENDED AND RESTATED 2024 STOCK INCENTIVE PLAN I. INTRODUCTION 1.1Purposes. The purposes of the Core Scientific, Inc. Amended and Restated 2024 Stock Incentive Plan (this “Plan”) are (i) to align the interests of the Company’s stockholders and the recipients of awards under this Plan by increasing the proprietary interest of such recipients in the Company’s growth and success

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission File

and Core Scientific, Inc., dated

EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) dated as of February 26, 2025 (the “Effective Date”) is made by and between Core Scientific, Inc.

Core Scientific Announces Fiscal First Quarter 2025 Results First Quarter 2025 Highlights

Exhibit 99.1 Core Scientific Announces Fiscal First Quarter 2025 Results First Quarter 2025 Highlights •On track to deliver 250MW of billable capacity to CoreWeave by the end of this year and anticipate entering 2026 with annualized colocation revenue of approximately $360 million. •First tranche of 8MW of billable capacity at Denton to be delivered to CoreWeave by the end of this month and an add

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 00

Restricted Stock Unit Award Agreement pursuant to Core Scientific, Inc. 2024 Stock Incentive Plan

CORE SCIENTIFIC, INC. 2024 STOCK INCENTIVE PLAN Restricted Stock Unit Award Notice You have been awarded a restricted stock unit award with respect to shares of Common Stock of Core Scientific, Inc., a Delaware corporation (the “Company”), pursuant to the terms and conditions of the Core Scientific, Inc. 2024 Stock Incentive Plan (the “Plan”) and the Restricted Stock Unit Award Agreement (together

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission File

First Quarter 2025 Earnings Presentation Adam Sullivan, CEO Jim Nygaard, CFO Matt Brown, COO May 7, 2025 2 FORWARD-LOOKING STATEMENTS This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Pr

First Quarter 2025 Earnings Presentation Adam Sullivan, CEO Jim Nygaard, CFO Matt Brown, COO May 7, 2025 2 FORWARD-LOOKING STATEMENTS This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding projections, estimates and forecasts of revenue and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2025 Core Scientific, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2025 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission Fi

Core Scientific, Inc. 10,795,751 Shares of Common Stock

Prospectus Supplement No. 32 (to Prospectus dated May 3, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278676 Core Scientific, Inc. 10,795,751 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated May 3, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-278676). This prospec

Core Scientific Announces March 2025 Production and Operations Updates Earned 247 Self-Mined Bitcoin for a Total of 718 Bitcoin Year-to-Date and Our Customers Earned an Estimated 17 Bitcoin at Our Data Centers in March

press release corescientific.com Core Scientific Announces March 2025 Production and Operations Updates Earned 247 Self-Mined Bitcoin for a Total of 718 Bitcoin Year-to-Date and Our Customers Earned an Estimated 17 Bitcoin at Our Data Centers in March AUSTIN, Texas, April 7, 2025 – Core Scientific, Inc. (Nasdaq: CORZ) ("Core Scientific" or “the Company”), a leader in digital infrastructure for hig

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2025 Core Scientific, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2025 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission Fil

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

ARS

81,7('67$7(6 6(&85,7,(6$1 '(;&+$1*(&200,66,21  :DVKLQJWRQ'&  )250.

to the Securities and Exchange Commission, dated

March 13, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Core Scientific, Inc. under Item 4.01 of its Form 8-K dated March 12, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Core Scientific, Inc. contained therein. Very

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2025 Core Scientific, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2025 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission Fi

Core Scientific, Inc. 10,795,751 Shares of Common Stock

Prospectus Supplement No. 31 (to Prospectus dated May 3, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278676 Core Scientific, Inc. 10,795,751 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated May 3, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-278676). This prospec

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

Core Scientific, Inc. 10,795,751 Shares of Common Stock

Prospectus Supplement No. 30 (to Prospectus dated May 3, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278676 Core Scientific, Inc. 10,795,751 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated May 3, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-278676). This prospec

Core Scientific, Inc. 10,795,751 Shares of Common Stock

Prospectus Supplement No. 29 (to Prospectus dated May 3, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278676 Core Scientific, Inc. 10,795,751 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated May 3, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-278676). This prospec

March 5, 2025 Core Scientific Announces February 2025 Production and Operations Updates Earned 215 Self-Mined Bitcoin for a Total of 471 Bitcoin Year-to-Date and Our Customers Earned an Estimated 16 Bitcoin at Our Data Centers in February AUSTIN, Tex

March 5, 2025 Core Scientific Announces February 2025 Production and Operations Updates Earned 215 Self-Mined Bitcoin for a Total of 471 Bitcoin Year-to-Date and Our Customers Earned an Estimated 16 Bitcoin at Our Data Centers in February AUSTIN, Texas-(BUSINESS WIRE)- Core Scientific, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 Core Scientific, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2025 Core Scientific, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2025 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission Fil

Core Scientific Announces Planned CFO Transition Company Welcomes Veteran Finance Executive, Jim Nygaard, as New CFO Effective March 17

Exhibit 99.1 Core Scientific Announces Planned CFO Transition Company Welcomes Veteran Finance Executive, Jim Nygaard, as New CFO Effective March 17 March 3, 2025 AUSTIN, Texas-(BUSINESS WIRE)- Core Scientific, Inc. (NASDAQ: CORZ) (“Core Scientific” or the “Company”), a leader in digital infrastructure for high-performance computing (HPC), today announced that Jim Nygaard will succeed Denise Sterl

Insider Trading Policy

exhibit19insidertradingp 106 E. 6th Street, Suite 900-145, Austin TX 78701 www.corescientific.com | 425-998-5300 Insider Trading Policy I. Policy Principles • Employees, officers, directors, and designated consultants (each a “Covered Person,” and collectively, “Covered Persons”) of Core Scientific, Inc. and its subsidiaries (together, the “Company”) are responsible for understanding the obligatio

Core Scientific and CoreWeave Announce $1.2 Billion Expansion at Denton, TX Site Expands Total Contracted HPC Infrastructure by CoreWeave to Approximately 590 Megawatts of Critical IT Load at Six Core Scientific Sites New Agreement Boosts Total Contr

press release corescientific.com Core Scientific and CoreWeave Announce $1.2 Billion Expansion at Denton, TX Site Expands Total Contracted HPC Infrastructure by CoreWeave to Approximately 590 Megawatts of Critical IT Load at Six Core Scientific Sites New Agreement Boosts Total Contracted Revenue to $10.2 Billion over 12-year Contract Terms AUSTIN, Texas – February 26, 2025 – Core Scientific, Inc.

ist of Subsidiaries

Exhibit 21.1 Subsidiaries of Core Scientific, Inc. Name of Subsidiary Jurisdiction of Incorporation American Property Acquisition, LLC Delaware American Property Acquisition I, LLC North Carolina American Property Acquisitions VII, LLC Georgia Core Scientific Mining (Oklahoma) LLC Delaware

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-400

Core Scientific, Inc. 10,795,751 Shares of Common Stock

Prospectus Supplement No. 27 (to Prospectus dated May 3, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278676 Core Scientific, Inc. 10,795,751 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated May 3, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-278676). This prospec

Core Scientific, Inc. 10,795,751 Shares of Common Stock

Prospectus Supplement No. 28 (to Prospectus dated May 3, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278676 Core Scientific, Inc. 10,795,751 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated May 3, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-278676). This prospec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 Core Scientific

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission

Fourth Quarter Fiscal 2024 Earnings Presentation Adam Sullivan, CEO Denise Sterling, CFO February 26, 2025 2 FORWARD-LOOKING STATEMENTS This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the

Fourth Quarter Fiscal 2024 Earnings Presentation Adam Sullivan, CEO Denise Sterling, CFO February 26, 2025 2 FORWARD-LOOKING STATEMENTS This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding projections, estimates and forecasts of revenue a

Core Scientific Announces Fiscal Fourth Quarter and Full Fiscal Year 2024 Results Fourth Quarter 2024 Highlights

press release Exhibit 99.1 corescientific.com Core Scientific Announces Fiscal Fourth Quarter and Full Fiscal Year 2024 Results Fourth Quarter 2024 Highlights •Incurred net loss of $265.5 million due primarily to a $224.7 million non-cash mark-to-market adjustment to warrants and other contingent value right liabilities required by the significant year-over-year increase in our share price •Report

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the common stock, par val

Core Scientific Announces January 2025 Production and Operations Updates Earned 256 Self-Mined Bitcoin; Our Customers Earned an Estimated 17 Bitcoin at Our Data Centers in January

press release corescientific.com Core Scientific Announces January 2025 Production and Operations Updates Earned 256 Self-Mined Bitcoin; Our Customers Earned an Estimated 17 Bitcoin at Our Data Centers in January AUSTIN, Texas, January 5, 2025 – Core Scientific, Inc. (Nasdaq: CORZ) ("Core Scientific" or “the Company”), a leader in digital infrastructure for high-performance computing and bitcoin m

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2025 Core Scientific,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2025 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission

Core Scientific, Inc. 10,795,751 Shares of Common Stock

Prospectus Supplement No. 26 (to Prospectus dated May 3, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278676 Core Scientific, Inc. 10,795,751 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated May 3, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-278676). This prospec

Core Scientific Announces December 2024 Production and Operations Updates Earned 291 Self-Mined Bitcoin for a Total of 6,595 Bitcoin Year-to-Date and 974 in the Fourth Quarter; Our Customers Earned an Estimated 18 Bitcoin at Our Data Centers in Decem

press release Exhibit 99.1 corescientific.com Core Scientific Announces December 2024 Production and Operations Updates Earned 291 Self-Mined Bitcoin for a Total of 6,595 Bitcoin Year-to-Date and 974 in the Fourth Quarter; Our Customers Earned an Estimated 18 Bitcoin at Our Data Centers in December AUSTIN, Texas, December 6, 2024 – Core Scientific, Inc. (Nasdaq: CORZ) ("Core Scientific" or “the Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2025 Core Scientific,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2025 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission F

Core Scientific, Inc. 10,795,751 Shares of Common Stock

Prospectus Supplement No. 25 (to Prospectus dated May 3, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278676 Core Scientific, Inc. 10,795,751 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated May 3, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-278676). This prospec

Core Scientific, Inc. 10,795,751 Shares of Common Stock

Prospectus Supplement No. 23 (to Prospectus dated May 3, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278676 Core Scientific, Inc. 10,795,751 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated May 3, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-278676). This prospec

Core Scientific, Inc. 10,795,751 Shares of Common Stock

Prospectus Supplement No. 24 (to Prospectus dated May 3, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278676 Core Scientific, Inc. 10,795,751 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated May 3, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-278676). This prospec

Indenture, dated as of December 5, 2024, by and between the Company and U.S. Bank Trust Company, National Association, as Trustee.

Exhibit 4.1 ═══════════════════════════════════════════════════════ ═══════════════════════════════════════════════════════ CORE SCIENTIFIC, INC. and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee ───────────────────── INDENTURE Dated as of December 5, 2024 ───────────────────── 0.00% Convertible Senior Notes due 2031 ═══════════════════════════════════════════════════════ ══════════════

Core Scientific Announces Proposed Convertible Senior Notes Offering

Exhibit 99.1 Core Scientific Announces Proposed Convertible Senior Notes Offering December 2, 2024 AUSTIN, Texas- Core Scientific, Inc. (NASDAQ: CORZ) (“Core Scientific” or the “Company”), a leader in digital infrastructure for bitcoin mining and high-performance computing, today announced its intention to offer, subject to market and other conditions, $500 million aggregate principal amount of co

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2024 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2024 Core Scientific,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2024 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission

Core Scientific Announces November 2024 Production and Operations Updates Earned 314 Self-Mined Bitcoin for a Total of 6,304 Bitcoin Year-to-Date and Our Customers Earned an Estimated 29 Bitcoin at Our Data Centers in November

Exhibit 99.1 press release corescientific.com Core Scientific Announces November 2024 Production and Operations Updates Earned 314 Self-Mined Bitcoin for a Total of 6,304 Bitcoin Year-to-Date and Our Customers Earned an Estimated 29 Bitcoin at Our Data Centers in November AUSTIN, Texas, November 5, 2024 – Core Scientific, Inc. (Nasdaq: CORZ) ("Core Scientific" or “the Company”), a leader in digita

Core Scientific Prices Upsized $550 Million Convertible Senior Notes Offering

Exhibit 99.2 Core Scientific Prices Upsized $550 Million Convertible Senior Notes Offering December 3, 2024 AUSTIN, Texas- Core Scientific, Inc. (NASDAQ: CORZ) (“Core Scientific” or the “Company”), a leader in digital infrastructure for bitcoin mining and high-performance computing, today announced the pricing of its offering of $550 million aggregate principal amount of 0.00% convertible senior n

Core Scientific, Inc. 10,795,751 Shares of Common Stock

Prospectus Supplement No. 22 (to Prospectus dated May 3, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278676 Core Scientific, Inc. 10,795,751 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated May 3, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-278676). This prospec

Core Scientific, Inc. 10,795,751 Shares of Common Stock

424B3 1 a11624prospectussupplement.htm 424B3 Prospectus Supplement No. 21 (to Prospectus dated May 3, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278676 Core Scientific, Inc. 10,795,751 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated May 3, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amende

Core Scientific, Inc. 10,795,751 Shares of Common Stock

Prospectus Supplement No. 20 (to Prospectus dated May 3, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278676 Core Scientific, Inc. 10,795,751 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated May 3, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-278676). This prospec

Core Scientific, Inc. 10,795,751 Shares of Common Stock

Prospectus Supplement No. 19 (to Prospectus dated May 3, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278676 Core Scientific, Inc. 10,795,751 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated May 3, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-278676). This prospec

Core Scientific Announces Approval of Lease Amendments with the City of Denton to Enable High-Performance Computing Expansion

press release Exhibit 99.1 corescientific.com Core Scientific Announces Approval of Lease Amendments with the City of Denton to Enable High-Performance Computing Expansion Company growth continues in support of high-performance compute customers Denton, TX, Nov. 20, 2024 – Core Scientific Inc. (Nasdaq: CORZ) (“Core Scientific” or the “Company”), a leader in digital infrastructure for high-performa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2024 Core Scientific

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2024 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission

CORZ / Core Scientific, Inc. / BlackRock, Inc. Passive Investment

SC 13G 1 us21874a1060110824.txt us21874a1060110824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) Core Scientific - (Name of Issuer) Common Stock - (Title of Class of Securities) 21874A106 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40046

Core Scientific Announces Fiscal Third Quarter 2024 Results Fiscal Third Quarter 2024 Highlights

press release Exhibit 99.1 corescientific.com Core Scientific Announces Fiscal Third Quarter 2024 Results Fiscal Third Quarter 2024 Highlights •Incurred net loss of $455.3 million due primarily to a net $408.5 million non-cash mark-to-market adjustment to our warrants and other contingent value right liabilities required as a result of significant quarter-over-quarter increase in the value of our

Third Quarter Fiscal 2024 Earnings Presentation Adam Sullivan, CEO Denise Sterling, CFO November 6, 2024 2 FORWARD-LOOKING STATEMENTS This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Pr

Third Quarter Fiscal 2024 Earnings Presentation Adam Sullivan, CEO Denise Sterling, CFO November 6, 2024 2 FORWARD-LOOKING STATEMENTS This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding projections, estimates and forecasts of revenue and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2024 Core Scientific,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2024 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission

Core Scientific Announces October 2024 Production and Operations Updates Earned 369 Self-Mined Bitcoin for a Total of 5,990 Bitcoin Year-to-Date and Our Customers Earned an Estimated 52 Bitcoin at Our Data Centers in October

press release Exhibit 99.1 corescientific.com Core Scientific Announces October 2024 Production and Operations Updates Earned 369 Self-Mined Bitcoin for a Total of 5,990 Bitcoin Year-to-Date and Our Customers Earned an Estimated 52 Bitcoin at Our Data Centers in October AUSTIN, Texas, November 5, 2024 – Core Scientific, Inc. (Nasdaq: CORZ) ("Core Scientific" or “the Company”), a leader in digital

CORZ / Core Scientific, Inc. / BlackRock, Inc. Passive Investment

us21874a1060102424.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) Core Scientific - (Name of Issuer) Common Stock - (Title of Class of Securities) 21874A106 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh

Core Scientific Announces Exercise of Final Contract Option by CoreWeave for Delivery of Approximately 120 MW of Additional Digital Infrastructure to Host High-Performance Computing Operations Expands Total Contracted HPC Infrastructure by CoreWeave

press release corescientific.com Core Scientific Announces Exercise of Final Contract Option by CoreWeave for Delivery of Approximately 120 MW of Additional Digital Infrastructure to Host High-Performance Computing Operations Expands Total Contracted HPC Infrastructure by CoreWeave to Approximately 500 Megawatts of Critical IT Load at Six Core Scientific Sites Increases Potential Cumulative Revenu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2024 Core Scientific,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2024 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission

Core Scientific, Inc. 10,795,751 Shares of Common Stock

Prospectus Supplement No. 18 (to Prospectus dated May 3, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278676 Core Scientific, Inc. 10,795,751 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated May 3, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-278676). This prospec

Core Scientific Announces September 2024 Production and Operations Updates Earned 345 Self-Mined Bitcoin in September for a Total of 5,621 Bitcoin Year-to-Date and 1,115 in the Third Quarter; Clients Earned an Estimated 66 Bitcoin at Our Data Centers

press release corescientific.com Core Scientific Announces September 2024 Production and Operations Updates Earned 345 Self-Mined Bitcoin in September for a Total of 5,621 Bitcoin Year-to-Date and 1,115 in the Third Quarter; Clients Earned an Estimated 66 Bitcoin at Our Data Centers in September AUSTIN, Texas, September 7, 2024 – Core Scientific, Inc. (Nasdaq: CORZ) ("Core Scientific" or “the Comp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2024 Core Scientific,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2024 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission F

Core Scientific, Inc. 10,795,751 Shares of Common Stock

Prospectus Supplement No. 17 (to Prospectus dated May 3, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278676 Core Scientific, Inc. 10,795,751 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated May 3, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-278676). This prospec

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2024 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission

Form of Restricted Stock Unit Award Agreement pursuant to Core Scientific, Inc. 2024 Stock Incentive Plan

EX-10.2 3 exhibit102-formofrestricte.htm EX-10.2 Exhibit 10.2 CORE SCIENTIFIC, INC. 2024 STOCK INCENTIVE PLAN Restricted Stock Unit Award Notice Denise Sterling You have been awarded a restricted stock unit award with respect to shares of Common Stock of Core Scientific, Inc., a Delaware corporation (the “Company”), pursuant to the terms and conditions of the Core Scientific, Inc. 2024 Stock Incen

Transition and Separation Agreement, by and between Denise Sterling and Core Scientific, Inc., dated September 5, 2024

EX-10.1 2 exhibit101-transitionandse.htm EX-10.1 Exhibit 10.1 TRANSITION AND SEPARATION AGREEMENT This TRANSITION AND SEPARATION AGREEMENT (this “Agreement”) dated as of September 4, 2024 is made by and between Core Scientific, Inc. (the “Company”) and Denise Sterling (the “Executive”). WHEREAS, the Executive has been employed by the Company as Executive Vice President and Chief Financial Officer;

Core Scientific Announces CFO Transition Plan

Exhibit 99.1 press release corescientific.com Core Scientific Announces CFO Transition Plan AUSTIN, Texas – September 6, 2024 – Core Scientific, Inc. (NASDAQ: CORZ) (“Core Scientific” or the “Company”), a leader in digital infrastructure for bitcoin mining and high-performance computing, today announced that Denise Sterling has decided to step down from her role as Executive Vice President and Chi

Core Scientific, Inc. 10,795,751 Shares of Common Stock

Prospectus Supplement No. 16 (to Prospectus dated May 3, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278676 Core Scientific, Inc. 10,795,751 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated May 3, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-278676). This prospec

Core Scientific Announces August 2024 Production and Operations Updates Earned 358 Self-Mined Bitcoin for a Total of 5,275 Bitcoin Year-to-Date and Our Customers Earned an Estimated 90 Bitcoin at Our Data Centers in August

press release corescientific.com Core Scientific Announces August 2024 Production and Operations Updates Earned 358 Self-Mined Bitcoin for a Total of 5,275 Bitcoin Year-to-Date and Our Customers Earned an Estimated 90 Bitcoin at Our Data Centers in August AUSTIN, Texas, Sept. 5, 2024 – Core Scientific, Inc. (Nasdaq: CORZ) ("Core Scientific" or “the Company”), a leader in digital infrastructure for

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2024 Core Scientific

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2024 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission

Core Scientific Announces Proposed Convertible Senior Notes Offering

Core Scientific Announces Proposed Convertible Senior Notes Offering August 13, 2024 AUSTIN, Texas- Core Scientific, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Core Scientific,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission F

Core Scientific Prices Upsized $400 Million Convertible Senior Notes Offering

Core Scientific Prices Upsized $400 Million Convertible Senior Notes Offering August 14, 2024 AUSTIN, Texas- Core Scientific, Inc.

NOTICE OF FULL REDEMPTION CORE SCIENTIFIC, INC. 12.50% Secured Notes due 2028 (the “Notes”) CUSIP No. 21874A AA4 ISIN NO: US21874AAA43

NOTICE OF FULL REDEMPTION CORE SCIENTIFIC, INC. 12.50% Secured Notes due 2028 (the “Notes”) CUSIP No. 21874A AA4 ISIN NO: US21874AAA43 NOTICE IS HEREBY GIVEN TO THE HOLDERS of the above-referenced Notes Pursuant to Section 3.09 of the Indenture, dated as of January 23, 2024 (the “Indenture”) by and among Core Scientific, Inc., as Issuer (the “Issuer”), the guarantors party thereto from time to tim

CORZ / Core Scientific, Inc. / Beryl Capital Management LLC Passive Investment

SC 13G 1 corescientific13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Core Scientific, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 21874A106 (CUSIP Number) August 9, 2024 (Date of Event Which Requires Filing of this Statement) Check the appro

Core Scientific, Inc. 10,795,751 Shares of Common Stock

Prospectus Supplement No. 15 (to Prospectus dated May 3, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278676 Core Scientific, Inc. 10,795,751 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated May 3, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-278676). This prospec

Indenture, dated as of August 19, 2024, by and between the Company and U.S. Bank Trust Company, National Association, as Trustee.

EXECUTION VERSION ═══════════════════════════════════════════════════════ ═══════════════════════════════════════════════════════ CORE SCIENTIFIC, INC.

Second Quarter Fiscal 2024 Earnings Presentation Adam Sullivan, CEO Denise Sterling, CFO August 7, 2024 2 FORWARD-LOOKING STATEMENTS This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Pri

Second Quarter Fiscal 2024 Earnings Presentation Adam Sullivan, CEO Denise Sterling, CFO August 7, 2024 2 FORWARD-LOOKING STATEMENTS This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding projections, estimates and forecasts of revenue and

Core Scientific, Inc. 10,795,751 Shares of Common Stock

Prospectus Supplement No. 14 (to Prospectus dated May 3, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278676 Core Scientific, Inc. 10,795,751 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated May 3, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-278676). This prospec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40046 Core

Core Scientific Announces Fiscal Second Quarter 2024 Results Fiscal Second Quarter 2024 Highlights

press release Exhibit 99.1 corescientific.com Core Scientific Announces Fiscal Second Quarter 2024 Results Fiscal Second Quarter 2024 Highlights •Incurred net loss of $804.9 million due primarily to a net $796.0 million non-cash mark-to-market adjustment to our warrants and other contingent value right liabilities required as a result of significant quarter-over-quarter increase in the value of ou

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 Core Scientific, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission Fi

Core Scientific, Inc. 10,795,751 Shares of Common Stock

Prospectus Supplement No. 13 (to Prospectus dated May 3, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278676 Core Scientific, Inc. 10,795,751 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated May 3, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-278676). This prospec

Core Scientific Announces Exercise of Additional Contract Option by CoreWeave for Delivery of Approximately 112 MW of Additional Infrastructure to Host High-Performance Computing Operations Expands Total Contracted HPC Infrastructure by CoreWeave to

Exhibit 99.1 press release corescientific.com Core Scientific Announces Exercise of Additional Contract Option by CoreWeave for Delivery of Approximately 112 MW of Additional Infrastructure to Host High-Performance Computing Operations Expands Total Contracted HPC Infrastructure by CoreWeave to 382 Megawatts at Five Core Scientific sites Increases Potential Cumulative Revenue to More than $6.7 Bil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 Core Scientific, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission Fi

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission Fi

Core Scientific, Inc. 10,795,751 Shares of Common Stock

Prospectus Supplement No. 12 (to Prospectus dated May 3, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278676 Core Scientific, Inc. 10,795,751 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated May 3, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-278676). This prospec

Core Scientific Announces July 2024 Production and Operations Updates Earned 411 Self-Mined Bitcoin for a Total of 4,917 Bitcoin Year-to-Date and Our Customers Earned an Estimated 109 Bitcoin at Our Data Centers in July First Bitcoin Miner to Support

press release corescientific.com Core Scientific Announces July 2024 Production and Operations Updates Earned 411 Self-Mined Bitcoin for a Total of 4,917 Bitcoin Year-to-Date and Our Customers Earned an Estimated 109 Bitcoin at Our Data Centers in July First Bitcoin Miner to Support Foundry Donate, a Program to Fund Bitcoin Network Core Developers AUSTIN, Texas, August 5, 2024 – Core Scientific, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2024 Core Scientific, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2024 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission Fil

Employment Agreement, by and between Todd M. DuChene and Core Scientific, Inc., dated July 19, 2024

Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) dated as of July 19, 2024 (the “Effective Date”) is made by and between Core Scientific, Inc. (the “Company”) and Todd DuChene (the “Executive”). WHEREAS, the Executive has been employed by the Company as Executive Vice President, Chief Legal and Administrative Officer, Chief Compliance Officer and Secretary; and WHEREA

Form of Performance Share Unit Award Agreement pursuant to Core Scientific, Inc. 2024 Stock Incentive Plan

Exhibit 10.2 CORE SCIENTIFIC, INC. 2024 STOCK INCENTIVE PLAN Restricted Stock Unit Award Notice Recipient You have been awarded a restricted stock unit award with respect to shares of Common Stock of Core Scientific, Inc., a Delaware corporation (the “Company”), pursuant to the terms and conditions of the Core Scientific, Inc. 2024 Stock Incentive Plan (the “Plan”) and the Restricted Stock Unit Aw

Core Scientific, Inc. 10,795,751 Shares of Common Stock

Prospectus Supplement No. 11 (to Prospectus dated May 3, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278676 Core Scientific, Inc. 10,795,751 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated May 3, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-278676). This prospec

Form of Performance Share Unit Award Agreement pursuant to Core Scientific, Inc. 2024 Stock Incentive Plan

Exhibit 10.3 CORE SCIENTIFIC, INC. 2024 STOCK INCENTIVE PLAN Performance Share Unit Award Notice Recipient You have been awarded a performance share unit award with respect to shares of Common Stock of Core Scientific, Inc., a Delaware corporation (the “Company”), pursuant to the terms and conditions of the Core Scientific, Inc. 2024 Stock Incentive Plan (the “Plan”) and the Performance Share Unit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2024 Core Scientific, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2024 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission Fil

Core Scientific, Inc. 10,795,751 Shares of Common Stock

Prospectus Supplement No. 10 (to Prospectus dated May 3, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278676 Core Scientific, Inc. 10,795,751 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated May 3, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-278676). This prospec

Core Scientific Announces Tranche 2 Warrants Triggering Event Strong Share Price Performance Makes Tranche 2 Warrants Exercisable until January 23, 2029

Exhibit 99.1 press release corescientific.com Core Scientific Announces Tranche 2 Warrants Triggering Event Strong Share Price Performance Makes Tranche 2 Warrants Exercisable until January 23, 2029 AUSTIN, Texas – July 12, 2024 – Core Scientific, Inc. (NASDAQ: CORZ) (“Core Scientific” or the “Company”), one of the largest owners and operators of high-powered digital infrastructure for bitcoin min

Core Scientific, Inc. 10,795,751 Shares of Common Stock

Prospectus Supplement No. 9 (to Prospectus dated May 3, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278676 Core Scientific, Inc. 10,795,751 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated May 3, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-278676). This prospect

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2024 Core Scientific, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2024 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission File

Core Scientific Announces Mandatory Conversion of Outstanding Secured Convertible Notes Strong Business Momentum and Share Trading Performance Trigger Conversion of Outstanding Convertible Notes, Completing the Elimination of $260 Million of Debt fro

press release corescientific.com Core Scientific Announces Mandatory Conversion of Outstanding Secured Convertible Notes Strong Business Momentum and Share Trading Performance Trigger Conversion of Outstanding Convertible Notes, Completing the Elimination of $260 Million of Debt from Balance Sheet AUSTIN, Texas – July 8, 2024 – Core Scientific, Inc. (NASDAQ: CORZ) (“Core Scientific” or the “Compan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2024 Core Scientific, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2024 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission File

Core Scientific Announces June 2024 Production and Operations Updates Secured High-Performance Computing (HPC) Hosting Contracts with CoreWeave for 270 MW of Infrastructure, Representing Total Revenue Opportunity of More than $4.7 Billion over 12-Yea

press release corescientific.com Core Scientific Announces June 2024 Production and Operations Updates Secured High-Performance Computing (HPC) Hosting Contracts with CoreWeave for 270 MW of Infrastructure, Representing Total Revenue Opportunity of More than $4.7 Billion over 12-Year Terms Earned 430 Self-Mined Bitcoin for a Total of 4,506 Bitcoin Year-to-Date and 1,680 in the Second Quarter; Clie

Core Scientific, Inc. 10,795,751 Shares of Common Stock

Prospectus Supplement No. 8 (to Prospectus dated May 3, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278676 Core Scientific, Inc. 10,795,751 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated May 3, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-278676). This prospect

Core Scientific, Inc. 10,795,751 Shares of Common Stock

Prospectus Supplement No. 7 (to Prospectus dated May 3, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278676 Core Scientific, Inc. 10,795,751 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated May 3, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-278676). This prospect

Core Scientific, Inc. 10,795,751 Shares of Common Stock

424B3 1 prospectissupplement-64248.htm 424B3 Prospectus Supplement No. 2 (to Prospectus dated May 3, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278676 Core Scientific, Inc. 10,795,751 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated May 3, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended

Core Scientific, Inc. 10,795,751 Shares of Common Stock

Prospectus Supplement No. 5 (to Prospectus dated May 3, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278676 Core Scientific, Inc. 10,795,751 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated May 3, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-278676). This prospect

Core Scientific, Inc. 10,795,751 Shares of Common Stock

Prospectus Supplement No. 6 (to Prospectus dated May 3, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278676 Core Scientific, Inc. 10,795,751 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated May 3, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-278676). This prospect

Core Scientific, Inc. 10,795,751 Shares of Common Stock

Prospectus Supplement No. 4 (to Prospectus dated May 3, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278676 Core Scientific, Inc. 10,795,751 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated May 3, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-278676). This prospect

Core Scientific, Inc. 10,795,751 Shares of Common Stock

Prospectus Supplement No. 3 (to Prospectus dated May 3, 2024) Filed Pursuant to Rule 424(b)(3) Registration No. 333-278676 Core Scientific, Inc. 10,795,751 Shares of Common Stock This prospectus supplement updates and supplements the prospectus dated May 3, 2024 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1, as amended (Registration No. 333-278676). This prospect

Core Scientific Announces New Contract with CoreWeave for Delivery of Approximately 70 MW of Additional Infrastructure to Host High-Performance Computing Operations Marks Another Meaningful Step in Execution of Portfolio Diversification Strategy Incr

Exhibit 99.1 press release corescientific.com Core Scientific Announces New Contract with CoreWeave for Delivery of Approximately 70 MW of Additional Infrastructure to Host High-Performance Computing Operations Marks Another Meaningful Step in Execution of Portfolio Diversification Strategy Increases Total Owned and Contracted Infrastructure Allocated for HPC Hosting to Approximately 270 MW AUSTIN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 Core Scientific, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 Core Scientific, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission Fil

Form of Performance Share Unit Award Agreement pursuant to Core Scientific, Inc. 2024 Stock Incentive Plan

Exhibit 10.3 CORE SCIENTIFIC, INC. 2024 STOCK INCENTIVE PLAN Performance Share Unit Award Notice Recipient You have been awarded a performance share unit award with respect to shares of Common Stock of Core Scientific, Inc., a Delaware corporation (the “Company”), pursuant to the terms and conditions of the Core Scientific, Inc. 2024 Stock Incentive Plan (the “Plan”) and the Performance Share Unit

Form of Restricted Stock Unit Award Agreement pursuant to Core Scientific, Inc. 2024 Stock Incentive Plan

Exhibit 10.2 CORE SCIENTIFIC, INC. 2024 STOCK INCENTIVE PLAN Restricted Stock Unit Award Notice Recipient You have been awarded a restricted stock unit award with respect to shares of Common Stock of Core Scientific, Inc., a Delaware corporation (the “Company”), pursuant to the terms and conditions of the Core Scientific, Inc. 2024 Stock Incentive Plan (the “Plan”) and the Restricted Stock Unit Aw

Employment Agreement, by and between Adam Sullivan and Core Scientific, Inc., dated June 14, 2024

ex101corz-ceoemploymenta Execution Version EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) dated as of June , 2024 (the “Effective Date”) is made by and between Core Scientific, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 Core Scientific, In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission Fil

INVESTOR AND ANALYST DAY June 12, 2024 Denton, TX 2 FORWARD-LOOKING STATEMENTS This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, includi

corescientificinvestorda INVESTOR AND ANALYST DAY June 12, 2024 Denton, TX 2 FORWARD-LOOKING STATEMENTS This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics, projections of market opportunity and expectations, the Company’s ability to scale and grow its business, source clean and renewable energy, the advantages and expected growth of the Company and the Company’s ability to source and retain talent.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 Core Scientific, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission File

Core Scientific Rejects Unsolicited Proposal from CoreWeave Proposal Significantly Undervalues the Company and Is Not in the Best Interests of Core Scientific and its Shareholders Core Scientific Remains Focused on Executing Previously Announced Seri

Exhibit 99.1 press release corescientific.com Core Scientific Rejects Unsolicited Proposal from CoreWeave Proposal Significantly Undervalues the Company and Is Not in the Best Interests of Core Scientific and its Shareholders Core Scientific Remains Focused on Executing Previously Announced Series of 12-Year Contracts with CoreWeave, which Are Expected to Generate Over $3.5 Billion in Cumulative R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 Core Scientific, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission File

Core Scientific Announces May 2024 Production and Operations Updates

Exhibit 99.1 press release corescientific.com Core Scientific Announces May 2024 Production and Operations Updates •Earned 447 self-mined bitcoin for a total of 4,076 bitcoin year-to-date, and our customers earned an estimated 128 bitcoin at our data centers in May •Operated approximately 219,000 owned and hosted bitcoin miners for a total energized hash rate of 26.1 exahash as of May 31, 2024 AUS

1 JUNE 3, 2024 Core Scientific Announces Strategic Expansion of HPC Business with Multi-Year CoreWeave Hosting Agreements JUNE 3, 2024 2 JUNE 3, 2024 Forward-looking statements This presentation of Core Scientific, Inc. (the “Company”) includes “forw

finalcorzhpcreleaseslide 1 JUNE 3, 2024 Core Scientific Announces Strategic Expansion of HPC Business with Multi-Year CoreWeave Hosting Agreements JUNE 3, 2024 2 JUNE 3, 2024 Forward-looking statements This presentation of Core Scientific, Inc.

Core Scientific to Provide Approximately 200 MW of Infrastructure to Host CoreWeave’s High-Performance Computing Services, Capturing Significant AI Compute Opportunity Transforms and Expands Core Scientific’s Hosting Business and Earnings Power While

Exhibit 99.1 press release corescientific.com Core Scientific to Provide Approximately 200 MW of Infrastructure to Host CoreWeave’s High-Performance Computing Services, Capturing Significant AI Compute Opportunity Transforms and Expands Core Scientific’s Hosting Business and Earnings Power While Maintaining Bitcoin Mining Capacity and Growth Potential Long-Term Hosting Agreements Expected to Gener

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 Core Scientific, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 Core Scientific, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40046 86-1243837 (State or other jurisdiction of incorporation) (Commission File

As filed with the Securities and Exchange Commission on May 21, 2024

S-8 As filed with the Securities and Exchange Commission on May 21, 2024 No. 333-    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CORE SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 86-1243837 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer I

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) Core Scientific, Inc.